Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Epithalon · AEDG
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Tetrapeptide
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Telomerase/telomere effects studied in cells.
Evidence and critical reading
Reported scientific and empirical uses
Aging research · Sleep and circadian rhythms
Handbooks describe short repeated cycles for circadian rhythm and anti-aging. Their duration is a source claim rather than a demonstrated aging-prevention schedule.
Human evidence
No validated human lifespan extension follows from these cell experiments. Epithalamin extract studies are not equivalent evidence.
Preclinical evidence
2025 cell study includes cancer-cell ALT findings and a linked correction that must accompany review.
Critical reading and limitations
A 2025 study examined telomere length and maintenance pathways in cell lines, including cancer cells, and has a linked correction. It does not show longer human life or harmless telomere stimulation in every context.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by 2.pdf
5–10 mg · Total daily amount
- Frequency
- Daily
- Duration
- 20 days; source proposes repetition 1–2 times yearly.
- Route
- Subcutaneous
- Context
- Sleep/longevity per source.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual07 · Page 30 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Clinical chronic safety unknown; telomere elongation cannot be used as reassurance about cancer risk.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID40908429 · Cell experiment
Normal and cancer cell lines.
Cell-culture exposure.
Telomere-length and maintenance-mechanism changes.
Does not show longer human life; linked correction PMID41240216.
PMID22117547 · Cell experiment
HeLa cells/DNA assays.
Fluorescent peptides, in vitro.
Nuclear penetration/DNA interaction.
Labeling/culture are not patient-vial distribution or benefit.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Epitalon · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID22117547
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF.
October 16, 2026
- PMID40908429
Al-Dulaimi S, Thomas R, Matta S, Roberts T.
October 16, 2026
- PMID41240216
Al-Dulaimi S, Thomas R, Matta S, Roberts T.
October 16, 2026
- R06
- R24
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026